Welcome to our dedicated page for Evommune SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. received an amended Schedule 13G disclosure from BioDiscovery 6 FPCI, Andera Partners, Stephane Bergez and Francois Xavier Mauron regarding their holdings of Evommune common stock. BioDiscovery 6 is the record holder of 1,391,990 shares of common stock, which the reporting persons may be deemed to beneficially own through Andera as management company and its managing partners, Bergez and Mauron.
This position represents 3.9% of Evommune’s common stock, based on 36,018,372 shares outstanding as of May 5, 2026. The reporting persons report shared voting and dispositive power over 1,391,990 shares and no sole voting or dispositive power. They state that they own 5% or less of the class and expressly disclaim status as a group.
T. Rowe Price Associates, Inc. reports beneficial ownership of common stock of Evommune Inc. The firm holds 1,940,939 shares, representing 5.4% of the company’s common stock outstanding. All reported shares are subject to T. Rowe Price’s sole voting and sole dispositive power, with no shared voting or dispositive authority.
T. Rowe Price states that this report should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Evommune, Inc. reports substantially higher operating spend and losses as it advances multiple inflammatory-disease programs. For the quarter ended June 30, 2026, it generated no revenue and recorded a net loss of $32.2 million, or $0.89 per share, driven by research and development expenses of $26.4 million and general and administrative expenses of $8.5 million.
For the first half of 2026, the net loss was $53.9 million. In June 2026, a Phase 2b trial of EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint, and Evommune will cease that indication, while continuing Phase 2b studies in atopic dermatitis and migraine. A February 2026 private placement raised $117.2 million, contributing to $288.0 million in cash, cash equivalents and investments at June 30, 2026, which management expects will fund operations under the current plan through 2028.
Evommune, Inc. is a clinical-stage biotech developing therapies for chronic inflammatory diseases, with lead programs EVO756 and EVO301 in Phase 2 development. In June 2026, a Phase 2b trial of EVO756 in chronic spontaneous urticaria failed its primary endpoint, and development for that indication is being discontinued. EVO756 development continues in atopic dermatitis and migraine, with a Phase 2b AD readout expected in September 2026 and a new global Phase 2b migraine prophylaxis trial underway.
For the quarter ended June 30, 2026, Evommune reported no revenue, research and development expenses of $26,412 thousand and general and administrative expenses of $8,483 thousand, leading to a net loss of $32,246 thousand, compared with $13,565 thousand a year earlier. For the first half of 2026, the net loss was $53,920 thousand versus $28,122 thousand in 2025, reflecting higher clinical and public-company costs and the absence of prior-year license revenue.
Liquidity has strengthened following a February 2026 private placement of 4,494,279 shares at $27.88 per share, providing net proceeds of approximately $117.2 million. As of June 30, 2026, cash, cash equivalents and investments totaled $288.0 million, which management expects will fund operations and capital needs into 2028. The company also highlights evolving legal and compliance risks around its and partners’ use of AI technologies.
Evommune, Inc., a clinical-stage biotechnology company, reported second quarter 2026 results and highlighted progress across its inflammatory disease pipeline. Lead oral candidate EVO756 is in a fully enrolled Phase 2b trial in moderate-to-severe atopic dermatitis, with top-line data expected in September 2026, and a global Phase 2b migraine prophylaxis trial has recently begun, targeting top-line data in 2027. After a Phase 2b chronic spontaneous urticaria study failed to meet its primary endpoint, development of EVO756 in that indication was discontinued to prioritize atopic dermatitis and migraine. Injectable fusion protein EVO301 showed positive Phase 2a data in atopic dermatitis, with full results to be presented at an upcoming medical conference and a Phase 2b trial planned to start in mid-2027, while additional indications such as ulcerative colitis and certain cardiovascular-related inflammatory conditions are being evaluated.
For the quarter ended June 30, 2026, revenue was zero, research and development expense was $26.4 million, and general and administrative expense was $8.5 million, leading to a net loss of $32.2 million. For the first six months of 2026, net loss was $53.9 million. Cash, cash equivalents and investments totaled $288.0 million as of June 30, 2026, compared with $216.7 million at December 31, 2025, and the company states this provides cash runway through 2028.
Evommune, Inc. reports that the first patient has been dosed in a global Phase 2b clinical trial of its oral MRGPRX2 antagonist EVO756 for prophylactic treatment of migraine. The study targets adults with refractory migraine experiencing at least six migraine days per month.
The randomized, double-blind, placebo-controlled, dose-ranging trial will enroll approximately 330 patients across two active doses and placebo for 12 weeks of daily treatment, exploring doses up to 100 mg. The primary endpoint is change in monthly migraine days, with top-line data expected in 2027.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen report beneficial ownership of 1,910,489 shares of Evommune, Inc. common stock, representing 5.3% of the class as of July 15, 2026. The shares, held by Point72 Associates, carry shared voting and dispositive power only.
The reporting persons state that this statement should not be construed as an admission that they are beneficial owners of these shares for purposes of Section 13 of the Exchange Act.
Evommune, Inc. Chief Financial Officer Kyle Carver purchased 1,000 shares of common stock in an open-market transaction at $13.26 per share, bringing his direct holdings to 60,335 shares. A prior sale of 1,000 shares at $23.42 on May 28, 2026 triggered Section 16(b) short-swing profit rules, and he agreed to pay $10,160 of profit to Evommune.
Evommune, Inc. director Arthur S. Kirsch reported an indirect open-market purchase of 10,000 shares of common stock at a weighted average price of $13.30 per share. The shares are held by a family trust for which he is a trustee, and he disclaims beneficial ownership except for his proportionate pecuniary interest.
Evommune, Inc. furnished a Form 8-K and prospectus supplement reporting top-line results from the randomized, double-blind, placebo-controlled Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe chronic spontaneous urticaria (CSU). The trial enrolled 160 antihistamine-refractory CSU patients across the United States, Europe, Canada and Japan and tested three active dose regimens versus placebo.
The study did not meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. Based on these results, the company plans to cease development of EVO756 for CSU while continuing to evaluate the compound in other indications. The press release was issued and furnished as Exhibit 99.1 on June 29, 2026.